NSCLC

Boehringer flexes staying power of HER2-mutant lung cancer med

Tyrosine kinase inhibitor zongertinib has an "unparalleled" risk/benefit profile, Boehringer’s global head of oncology, SVP Itziar Canamasas, Ph.D., said.

Zoey Becker Apr 28, 2025 9:00am

iTeos drops one of 3 clinical assets from pipeline

Dec 12, 2024 3:10pm

FDA approves Novocure’s tumor field therapy for metastatic NSCLC

Oct 16, 2024 10:14am

Dupixent for cancer? Researchers test med as PD-1 booster

Dec 7, 2023 6:00am

Pfizer ends 5 programs amid cost-savings overhaul

Oct 31, 2023 11:21am

ASCO: Novocure's electric fields extend lung cancer survival

Jun 6, 2023 8:00am